Buscar
Eli Lilly and Co
LLYAñadir a la lista de seguimiento
989.570USD
+22.580+2.34%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
933.66BCap. mercado
35.09P/E TTM
Más Datos de Eli Lilly and Co Compañía
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Información de Eli Lilly and Co
Símbolo de cotizaciónLLY
Nombre de la empresaEli Lilly and Co
Fecha de salida a bolsaJul 09, 1970
Director ejecutivoRicks (David A)
Número de empleados47000
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 09
DirecciónLilly Corporate Ctr
CiudadINDIANAPOLIS
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal46285
Teléfono13172762000
Sitio Webhttps://www.lilly.com/
Símbolo de cotizaciónLLY
Fecha de salida a bolsaJul 09, 1970
Director ejecutivoRicks (David A)
Ejecutivos de Eli Lilly and Co
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
32.30K
+18.71%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.54K
+0.70%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
16.26K
+9.66%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
14.46K
+31.93%
Ms. Kimberly H. Johnson
Ms. Kimberly H. Johnson
Independent Director
Independent Director
3.27K
+0.67%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
32.30K
+18.71%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
Otro
3.91B
22.23%
Por regiónUSD
Nombre
Ganancia
Proporción
U.S.
11.30B
64.20%
Europe
3.50B
19.87%
Other foreign countries
1.69B
9.59%
China
560.40M
3.18%
Japan
554.70M
3.15%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Diabetes-Mounjaro
6.52B
37.02%
Diabetes-Zepbound
3.59B
20.39%
Oncology-Verzenio
1.47B
8.35%
Diabetes-Other Diabetes
1.06B
6.04%
Diabetes-Trulicity
1.05B
5.98%
Otro
3.91B
22.23%
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Lilly Endowment, Inc.
9.76%
Vanguard Capital Management, LLC
5.67%
PNC Investments LLC
5.43%
BlackRock Institutional Trust Company, N.A.
4.44%
State Street Investment Management (US)
3.75%
Otro
70.95%
Accionistas
Accionistas
Proporción
Lilly Endowment, Inc.
9.76%
Vanguard Capital Management, LLC
5.67%
PNC Investments LLC
5.43%
BlackRock Institutional Trust Company, N.A.
4.44%
State Street Investment Management (US)
3.75%
Otro
70.95%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
46.65%
Investment Advisor/Hedge Fund
19.18%
Foundation
9.76%
Research Firm
2.15%
Pension Fund
2.01%
Bank and Trust
1.85%
Insurance Company
1.48%
Sovereign Wealth Fund
1.37%
Hedge Fund
0.73%
Otro
14.83%
Participación institucional
Actualizado: dom., 5 de abr
Actualizado: dom., 5 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
6331
864.16M
91.72%
+69.01M
2025Q4
5995
789.04M
83.45%
-5.66M
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Lilly Endowment, Inc.
91.90M
9.73%
-293.54K
-0.32%
Jan 07, 2026
PNC Investments LLC
51.12M
5.41%
-23.07K
-0.05%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
41.84M
4.43%
-59.16K
-0.14%
Dec 31, 2025
State Street Investment Management (US)
35.36M
3.74%
+635.36K
+1.83%
Dec 31, 2025
Capital Research Global Investors
24.57M
2.6%
-521.52K
-2.08%
Dec 31, 2025
Fidelity Management & Research Company LLC
24.08M
2.55%
+1.39M
+6.13%
Dec 31, 2025
Geode Capital Management, L.L.C.
19.81M
2.1%
-7.82K
-0.04%
Dec 31, 2025
Capital World Investors
15.03M
1.59%
+61.85K
+0.41%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
Ver más
VanEck Pharmaceutical ETF
Proporción47.56%
iShares U.S. Pharmaceuticals ETF
Proporción25.23%
Harbor Health Care ETF
Proporción18.24%
Roundhill GLP-1 & Weight Loss ETF
Proporción16.7%
Health Care Select Sector SPDR Fund
Proporción14.06%
Proshares Ultra Health Care
Proporción13.57%
iShares U.S. Healthcare ETF
Proporción13.54%
Amplify Weight Loss Drug & Treatment ETF
Proporción11.93%
Fidelity MSCI Health Care Index ETF
Proporción11.73%
Goldman Sachs Future Health Care Equity ETF
Proporción10.84%
Dividendos
Un total de
15.37B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
May 04, 2026
LLY.NB Interim Cash Dividend of gross USD 1.73 paid on Jun 10, 2026 going ex on May 15, 2026
May 15, 2026
Jun 10, 2026
May 15, 2026
Dec 08, 2025
LLY.NB Interim Cash Dividend of gross USD 1.73 paid on Mar 10, 2026 going ex on Feb 13, 2026
Feb 13, 2026
Mar 10, 2026
Feb 13, 2026
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Ver más
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
